rss
Sex Transm Infect doi:10.1136/sti.2007.029512

Estimation of the impact of genital warts on health-related quality of life

  1. Sarah Woodhall (sarah.woodhall{at}hyms.ac.uk)
  1. Hull York Medical School, United Kingdom
    1. Tina Ramsey (tina.ramsey{at}york.nhs.uk)
    1. York Hospitals NHS Foundation Trust, United Kingdom
      1. Chun Cai (chun.cai{at}york.nhs.uk)
      1. Hull York Mendical School, United Kingdom
        1. Simon Crouch (simon.crouch{at}egu.york.ac.uk)
        1. University of York, United Kingdom
          1. Mark Jit (mark.jit{at}hpa.org.uk)
          1. Health Protection Agency, United Kingdom
            1. Yvonne Birks (yfb1{at}york.ac.uk)
            1. University of York, United Kingdom
              1. John Edmunds (john.edmunds{at}hpa.org.uk)
              1. Health Protection Agency, United Kingdom
                1. Rob Newton (rob.newton{at}egu.york.ac.uk)
                1. University of York, United Kingdom
                  1. Charles JN Lacey (charles.lacey{at}hyms.ac.uk)
                  1. Hull York Medical School, United Kingdom
                    • Published Online First 13 March 2008

                    Abstract

                    Objectives: One of the two new human papillomavirus (HPV) vaccines protects against HPV types 6 and 11, which cause over 95% of genital warts, in addition to protecting against HPV types 16 and 18. In anticipation of HPV vaccine implementation, we measured the impact of genital warts on health-related quality of life (HRQoL) to assess potential benefits of the quadrivalent over the bivalent vaccine.

                    Methods: Genitourinary medicine clinic patients' 18 years old with a current diagnosis of genital warts were eligible; 81 consented and were interviewed by a member of the research team. A generic HRQoL questionnaire the EQ-5D (comprising of EQ-5D index and EQ visual analogue scale (VAS) scores) and a disease-specific HRQoL instrument, the CECA10, were administered. Previously established UK population norms were used as a control group for EQ-5D comparisons.

                    Results: Cases (with genital warts) had lower EQ VAS and EQ-5D index scores than controls. After adjusting for age and sex a mean difference between cases and controls ≤30 years old (n=70) of 13.9 points (95%CI, 9.9 to 17.6, p<0.001) for the EQ VAS and 0.039 points (95%CI, 0.005 to 0.068, p=0.02) on the EQ-5D index was observed. The difference between cases and controls for the EQ VAS was especially notable in young females.

                    Conclusions: Genital warts are associated with a significant detriment to HRQoL. The potential added benefit of preventing most cases of genital warts by HPV vaccination

                    This Article

                    1. Abstract
                    2. PDF
                    3. A correction has been published
                    4. All versions of this article:
                      1. sti.2007.029512v1
                      2. 84/3/161most recent

                    Responses

                    1. Submit a response
                    2. No responses published

                    Register for free content

                    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

                    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.